These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33844998)

  • 1. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19.
    Agusti A; Torres F; Faner R
    Lancet Respir Med; 2021 Jul; 9(7):682-683. PubMed ID: 33844998
    [No Abstract]   [Full Text] [Related]  

  • 2. Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19?
    Kareemi H; Rosenberg H; Yadav K
    CJEM; 2021 Sep; 23(5):611-612. PubMed ID: 34279822
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhaled budesonide for early treatment of COVID-19.
    Zeitlinger M; Idzko M
    Lancet Respir Med; 2021 Jul; 9(7):e59. PubMed ID: 33991506
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhaled budesonide for early treatment of COVID-19.
    Choi JC; Kim WY
    Lancet Respir Med; 2021 Jul; 9(7):e60. PubMed ID: 33991507
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhaled budesonide for early treatment of COVID-19.
    San-Juan R; Fernández-Ruiz M; López-Medrano F; Aguado JM
    Lancet Respir Med; 2021 Jul; 9(7):e58. PubMed ID: 33991508
    [No Abstract]   [Full Text] [Related]  

  • 6. [Inhaled budesonide in the treatment of COVID-19].
    Kluge S; Nitschmann S; Scherer M
    Internist (Berl); 2021 Aug; 62(8):887-889. PubMed ID: 34191054
    [No Abstract]   [Full Text] [Related]  

  • 7. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial.
    Agustí A; De Stefano G; Levi A; Muñoz X; Romero-Mesones C; Sibila O; Lopez-Giraldo A; Plaza Moral V; Curto E; Echazarreta AL; Márquez SE; Pascual-Guàrdia S; Santos S; Marin A; Valdés L; Saldarini F; Salgado C; Casanovas G; Varea S; Ríos J; Faner R
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 35144989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose budesonide for early COVID-19.
    Lipworth B; Chan R; Misirovs R
    Lancet; 2021 Dec; 398(10317):2147. PubMed ID: 34895529
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose budesonide for early COVID-19.
    Berezowski I; Patel J; Shaw M; Pourmand A
    Lancet; 2021 Dec; 398(10317):2146-2147. PubMed ID: 34895527
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled Budesonide Reduces the Risk of Emergency Department Evaluation or Hospitalization in Early COVID-19.
    Ebell MH
    Am Fam Physician; 2021 Aug; 104(2):207-208. PubMed ID: 34383442
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhaled budesonide for mild COVID-19. Is there more to it than just airways?
    Rathi S; Ish P; Kalantri A; Kalantri S
    Adv Respir Med; 2021; 89(5):552-553. PubMed ID: 34668186
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
    Ramakrishnan S; Nicolau DV; Langford B; Mahdi M; Jeffers H; Mwasuku C; Krassowska K; Fox R; Binnian I; Glover V; Bright S; Butler C; Cane JL; Halner A; Matthews PC; Donnelly LE; Simpson JL; Baker JR; Fadai NT; Peterson S; Bengtsson T; Barnes PJ; Russell REK; Bafadhel M
    Lancet Respir Med; 2021 Jul; 9(7):763-772. PubMed ID: 33844996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
    Yu LM; Bafadhel M; Dorward J; Hayward G; Saville BR; Gbinigie O; Van Hecke O; Ogburn E; Evans PH; Thomas NPB; Patel MG; Richards D; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Shanyinde M; de Lusignan S; Andersson MI; Barnes PJ; Russell REK; Nicolau DV; Ramakrishnan S; Hobbs FDR; Butler CC;
    Lancet; 2021 Sep; 398(10303):843-855. PubMed ID: 34388395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can a low or moderate dose of inhaled budesonide replace oral non-steroidal anti-asthma treatment?
    de Azevedo MV; Coelho M; Mendes JA; de Almeida AB
    J Int Med Res; 1991; 19(3):280-8. PubMed ID: 1936515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment with inhaled budesonide for patients with mild obstructive lung diseases who continue to smoke: long-term benefits].
    Jébrak G
    Presse Med; 1999 Nov; 28(36):1986-7. PubMed ID: 10599265
    [No Abstract]   [Full Text] [Related]  

  • 16. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2021 Aug; 110(10):595-596. PubMed ID: 34344196
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects.
    Christensson C; Thorén A; Lindberg B
    Drug Saf; 2008; 31(11):965-88. PubMed ID: 18840017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled budesonide for mild asthma.
    König P
    N Engl J Med; 1995 Mar; 332(10):683; author reply 683-4. PubMed ID: 7845440
    [No Abstract]   [Full Text] [Related]  

  • 19. Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
    Aalbers R; Boorsma M; van der Woude HJ; Jonkers RE
    Respir Res; 2010 May; 11(1):66. PubMed ID: 20509942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis.
    Baker JR; Mahdi M; Nicolau DV; Ramakrishnan S; Barnes PJ; Simpson JL; Cass SP; Russell REK; Donnelly LE; Bafadhel M
    Lancet Respir Med; 2022 Jun; 10(6):545-556. PubMed ID: 35397798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.